Gain Therapeutics, Inc. – NASDAQ:GANX

Gain Therapeutics stock price today

$1.7
-0.06
-3.41%
Financial Health
0
1
2
3
4
5
6
7
8
9

Gain Therapeutics stock price monthly change

+27.54%
month

Gain Therapeutics stock price quarterly change

+27.54%
quarter

Gain Therapeutics stock price yearly change

-36.46%
year

Gain Therapeutics key metrics

Market Cap
41.64M
Enterprise value
46.83M
P/E
-2.98
EV/Sales
167.13
EV/EBITDA
-1.83
Price/Sales
190.83
Price/Book
2.83
PEG ratio
0.37
EPS
-1.5
Revenue
N/A
EBITDA
-21.35M
Income
-21.14M
Revenue Q/Q
-100%
Revenue Y/Y
-77.68%
Profit margin
-9260.29%
Oper. margin
-9364.89%
Gross margin
0%
EBIT margin
-9364.89%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Gain Therapeutics stock price history

Gain Therapeutics stock forecast

Gain Therapeutics financial statements

Gain Therapeutics, Inc. (NASDAQ:GANX): Profit margin
Jun 2023 0 -7.68M
Sep 2023 0 -4.71M
Dec 2023 64.8K -4.72M -7290.08%
Mar 2024 0 -4.01M
Gain Therapeutics, Inc. (NASDAQ:GANX): Analyst Estimates
Dec 2023 64.8K -4.72M -7290.08%
Mar 2024 0 -4.01M
Oct 2025 50K -5.12M -10248%
Dec 2025 50K -5.12M -10248%
  • Analysts Price target

  • Financials & Ratios estimates

Gain Therapeutics, Inc. (NASDAQ:GANX): Debt to assets
Jun 2023 18260874 7.16M 39.25%
Sep 2023 14097448 6.76M 48%
Dec 2023 18609331 6.03M 32.41%
Mar 2024 14577184 5.93M 40.72%
Gain Therapeutics, Inc. (NASDAQ:GANX): Cash Flow
Jun 2023 -5.02M 3.04M 2.19M
Sep 2023 -3.96M 1.92M 134.47K
Dec 2023 -5.66M 3.14M 9.56M
Mar 2024 -3.58M 3.01M -145.80K

Gain Therapeutics alternative data

Gain Therapeutics, Inc. (NASDAQ:GANX): Employee count
Aug 2023 28
Sep 2023 28
Oct 2023 28
Nov 2023 28
Dec 2023 28
Jan 2024 28
Feb 2024 28
Mar 2024 28
Apr 2024 28
May 2024 29
Jun 2024 29
Jul 2024 29

Gain Therapeutics other data

2.02% -8.14%
of GANX is owned by hedge funds
239.94K -966.81K
shares is hold by hedge funds

Gain Therapeutics, Inc. (NASDAQ:GANX): Insider trades (number of shares)
Period Buy Sel
Dec 2023 0 2026
Mar 2024 30000 0
Jul 2024 17000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
RICHMAN ERIC I director
Common Stock 12,000 $1.21 $14,520
Purchase
RICHMAN ERIC I director
Common Stock 5,000 $1.23 $6,150
Purchase
RILEY JEFFREY SCOTT director
Common Stock 30,000 $3.86 $115,770
Option
ALDER MATTHIAS director, officer: Chief Execut..
Restricted Stock Units 18,750 N/A N/A
Option
ALDER MATTHIAS director, officer: Chief Execut..
Common Stock 637 N/A N/A
Option
ALDER MATTHIAS director, officer: Chief Execut..
Common Stock 825 N/A N/A
Option
ALDER MATTHIAS director, officer: Chief Execut..
Common Stock 18,750 N/A N/A
Option
ALDER MATTHIAS director, officer: Chief Execut..
Restricted Stock Units 825 N/A N/A
Option
ALDER MATTHIAS director, officer: Chief Execut..
Restricted Stock Units 637 N/A N/A
Sale
ALDER MATTHIAS director, officer: Chief Execut..
Common Stock 206 $2.46 $507
Insider Compensation
Dr. Manolo Bellotto Ph.D. (1971) Pres & GM
$251,990
Mr. Eric I. Richman M.B.A. (1961) Chief Executive Officer & Director
$213,290
Mr. Salvatore Calabrese (1970) Chief Financial Officer
$117,110
Monday, 23 December 2024
globenewswire.com
Wednesday, 11 December 2024
globenewswire.com
Monday, 7 October 2024
globenewswire.com
Thursday, 3 October 2024
globenewswire.com
Monday, 30 September 2024
globenewswire.com
Thursday, 26 September 2024
globenewswire.com
Thursday, 19 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Tuesday, 9 July 2024
globenewswire.com
Monday, 8 July 2024
zacks.com
Monday, 1 July 2024
seekingalpha.com
Friday, 28 June 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
globenewswire.com
Tuesday, 25 June 2024
globenewswire.com
Friday, 14 June 2024
investorplace.com
Thursday, 13 June 2024
globenewswire.com
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Wednesday, 29 May 2024
seekingalpha.com
Tuesday, 14 May 2024
globenewswire.com
Friday, 3 May 2024
Zacks Investment Research
Wednesday, 17 April 2024
Zacks Investment Research
Wednesday, 10 April 2024
Zacks Investment Research
Friday, 15 March 2024
GlobeNewsWire
Wednesday, 24 January 2024
Zacks Investment Research
Friday, 22 December 2023
Seeking Alpha
Thursday, 14 December 2023
Zacks Investment Research
Wednesday, 22 November 2023
Zacks Investment Research
  • What's the price of Gain Therapeutics stock today?

    One share of Gain Therapeutics stock can currently be purchased for approximately $1.7.

  • When is Gain Therapeutics's next earnings date?

    Unfortunately, Gain Therapeutics's (GANX) next earnings date is currently unknown.

  • Does Gain Therapeutics pay dividends?

    No, Gain Therapeutics does not pay dividends.

  • How much money does Gain Therapeutics make?

    Gain Therapeutics has a market capitalization of 41.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.62% to 55.18K US dollars.

  • What is Gain Therapeutics's stock symbol?

    Gain Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GANX".

  • What is Gain Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Gain Therapeutics?

    Shares of Gain Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Gain Therapeutics's key executives?

    Gain Therapeutics's management team includes the following people:

    • Dr. Manolo Bellotto Ph.D. Pres & GM(age: 54, pay: $251,990)
    • Mr. Eric I. Richman M.B.A. Chief Executive Officer & Director(age: 64, pay: $213,290)
    • Mr. Salvatore Calabrese Chief Financial Officer(age: 55, pay: $117,110)
  • How many employees does Gain Therapeutics have?

    As Jul 2024, Gain Therapeutics employs 29 workers, which is 4% more then previous quarter.

  • When Gain Therapeutics went public?

    Gain Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 19 Mar 2021.

  • What is Gain Therapeutics's official website?

    The official website for Gain Therapeutics is gaintherapeutics.com.

  • Where are Gain Therapeutics's headquarters?

    Gain Therapeutics is headquartered at 4800 Montgomery Lane, Bethesda, MD.

  • How can i contact Gain Therapeutics?

    Gain Therapeutics's mailing address is 4800 Montgomery Lane, Bethesda, MD and company can be reached via phone at +30 15001556.

Gain Therapeutics company profile:

Gain Therapeutics, Inc.

gaintherapeutics.com
Exchange:

NASDAQ

Full time employees:

29

Industry:

Biotechnology

Sector:

Healthcare

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

4800 Montgomery Lane
Bethesda, MD 20814

CIK: 0001819411
ISIN: US36269B1052
CUSIP: 36269B105